The emerging role of Artificial Intelligence in proton therapy: A review.

Autor: Isaksson LJ; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan 20141, Italy., Mastroleo F; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan 20141, Italy., Vincini MG; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy. Electronic address: mariagiulia.vincini@ieo.it., Marvaso G; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan 20141, Italy. Electronic address: Giulia.marvaso@ieo.it., Zaffaroni M; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy., Gola M; Department of Human Histology and Embryology, Collegium Medicum, School of Medicine, University of Warmia and Mazury, Olsztyn 10-082, Poland., Mazzola GC; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy., Bergamaschi L; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy., Gaito S; Proton Clinical Outcomes Unit, The Christie NHS Proton Beam Therapy Centre, Manchester M20 4BX, UK; Division of Clinical Cancer Science, School of Medical Sciences, The University of Manchester Manchester M13 9PL, UK., Alongi F; Department of Advanced Radiation Oncology, IRCCS Sacro Cuore Don Calabria, 37024 Negrar-Verona, Italy & DSMC, University of Brescia, Brescia, Italy., Doyen J; Centre Antoine-Lacassagne, University of Côte d'Azur, Nice 06189, France; University Côte d'Azur, CNRS UMR 7284, INSERM U1081, Centre Antoine Lacassagne, Institute for Research on Cancer and Aging of Nice (IRCAN), 06189 Nice, France, Centre Antoine Lacassagne, Nice 06189, France., Fossati P; EBG MedAustron GmbH, Marie-Curie-Str. 5, Wiener Neustadt 2700, Austria; Department of General and Translational Oncology and Hematology, Karl Landsteiner University of Health Sciences, Krems an der Donau, 3500, Austria., Haustermans K; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium., Høyer M; Aarhus University (AU), Nordre Ringgade 1, Aarhus C 8000, Denmark., Langendijk JA; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Matute R; Centro de Protonterapia Quironsalud, Pozuelo de Alarcón, Madrid 28223, Spain., Orlandi E; Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy., Schwarz M; Radiation Oncology Department, University of Washington, Seattle, WA 98109, USA., Troost EGC; OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden 01309, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association/Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden 01307, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01309, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden 01328, Germany., Vondracek V; Proton Therapy Centre Czech, Prague, Czech Republic and Department of Health Care Disciplines and Population Protection, Faculty of Biomedical Engineering, Czech Technical University Prague, Kladno, Czech Republic., La Torre D; Department of Oncology and Hemato-Oncology, University of Milan, Milan 20141, Italy; SKEMA Business School, Université Côte d'Azur, Sophia Antipolis, France., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan 20141, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan 20141, Italy., Petralia G; Department of Oncology and Hemato-Oncology, University of Milan, Milan 20141, Italy; Division of Radiology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy., Orecchia R; Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan 20141, Italy., Alterio D; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy., Jereczek-Fossa BA; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan 20141, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan 20141, Italy.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2024 Dec; Vol. 204, pp. 104485. Date of Electronic Publication: 2024 Sep 02.
DOI: 10.1016/j.critrevonc.2024.104485
Abstrakt: Artificial intelligence (AI) has made a tremendous impact in the space of healthcare, and proton therapy is not an exception. Proton therapy has witnessed growing popularity in oncology over recent decades, and researchers are increasingly looking to develop AI and machine learning tools to aid in various steps of the treatment planning and delivery processes. This review delves into the emergent role of AI in proton therapy, evaluating its development, advantages, intended clinical contexts, and areas of application. Through the analysis of 76 studies, we aim to underscore the importance of AI applications in advancing proton therapy and to highlight their prospective influence on clinical practices.
Competing Interests: Declaration of Competing Interest BAJF received speaker fees from Roche, Bayer, Janssen, Ipsen, Accuray, Astellas, Elekta, IBA and Astra Zeneca (all outside the current project). EGCT is member of the scientific advisory board of IBA and received speaker fees from Elekta (all outside the current manuscript). M.G.V received a research fellowship from the Associazione Italiana per la Ricerca sul Cancro (AIRC) entitled “Radioablation ± hormonotherapy for prostate cancer oligorecurrences (RADIOSA trial): potential of imaging and biology” registered at Clinical Trials.gov NCT03940235, approved by the Ethics Committee of IEO and Centro Cardiologico Monzino (IEO-997). GC reports speakers fee and advisory board from Roche, Novartis, Lilly, Pfizer, Astra Zeneca, Daichii Sankyo, Ellipsis, Veracyte, Exact Science, Celcuity, Merck, BMS, Gilead, Sanofi, Menarini. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The remaining authors declare no conflicts of interest.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: